All Stories

  1. Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization
  2. Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
  3. Liquid chromatography–tandem mass spectrometry for clinical diagnostics
  4. Reduced Immune Response and Neutralizing Antibody Activity to the SARS-CoV-2 Vaccination in Patients with a History of Solid Organ Transplant
  5. Is the Best Drug Test the Enemy of the Good STAT Toxicology Screen?
  6. Drug testing in the era of new psychoactive substances
  7. The effect of the Covid-19 shutdown on glycemic testing and control
  8. Side-Effects of COVID-19 on Patient Care: An INR Story
  9. Adding Value to Clinical Toxicology Testing
  10. The 2018 AACC/SYCL PhD Clinical Chemist Compensation Survey
  11. Development and validation of a LC-MS/MS assay for quantification of serum estradiol using calibrators with values assigned by the CDC reference measurement procedure
  12. Serum 25-Hydroxyvitamin D Concentrations from Patient Groups at High Risk for Deficiency
  13. Commentary
  14. Comparison of four clinically validated testosterone LC-MS/MS assays: Harmonization is an attainable goal
  15. A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service
  16. The (Sun)Light and Dark of 25-Hydroxyvitamin D Testing
  17. Quantification of Serum Voriconazole, Isavuconazole, and Posaconazole by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
  18. A Case of Opioid Overdose? Or Is It?
  19. Advances in Clinical Mass Spectrometry
  20. Steroid hormones
  21. Advances in bioanalytical techniques to measure steroid hormones in serum
  22. Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant
  23. Development and validation of a liquid chromatography–tandem mass spectrometry (LC–MS/MS) assay to quantify serum voriconazole
  24. Genetic Data in Health Care: From Data to Information
  25. Development and Validation of a Liquid Chromatography–Tandem Mass Spectrometry Assay to Quantify Plasma Busulfan
  26. Interpreting Laboratory Results in Transgender Patients on Hormone Therapy
  27. The challenges of LC–MS/MS analysis of opiates and opioids in urine
  28. Direct total and free testosterone measurement by liquid chromatography tandem mass spectrometry across two different platforms
  29. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory
  30. The successful implementation of a licensed data management interface between a Sunquest® laboratory information system and an AB SCIEXTM mass spectrometer
  31. Development and validation of a serum total testosterone liquid chromatography–tandem mass spectrometry (LC–MS/MS) assay calibrated to NIST SRM 971
  32. In Reply
  33. Role of liquid chromatography–high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology
  34. A Mixed (Long- and Medium-chain) Triglyceride Lipid Emulsion Extracts Local Anesthetic from Human Serum In Vitro  More Effectively than a Long-chain Emulsion
  35. Hydrophilic interaction LC–MS/MS analysis of opioids in urine: significance of glucuronide metabolites
  36. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies
  37. PharmGKB summary
  38. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing
  39. Serum verapamil concentrations before and after Intralipid® therapy during treatment of an overdose
  40. A case of a rapid drop in lactate
  41. Vitamin D status of county hospital patients assessed by the DiaSorin LIAISON® 25-hydroxyvitamin D assay
  42. Choosing the Right Benzodiazepine Assay: Impact on Clinical Decision Making
  43. Lack of  -Hydroxybutyrate Prevalence Among An Urban Emergency Department Population
  44. Germline genomic variants associated with childhood acute lymphoblastic leukemia
  45. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
  46. Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia
  47. Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia
  48. Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs
  49. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
  50. Ancestry and pharmacogenetics of antileukemic drug toxicity
  51. Genetic Studies of a Cluster of Acute Lymphoblastic Leukemia Cases in Churchill County, Nevada
  52. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia
  53. Global gene expression as a function of germline genetic variation
  54. Gene Expression Profiles Distinguish Children Who Develop Therapy-Related Myeloid Leukemia.
  55. Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.
  56. A preliminary evaluation of the functional significance of alpha-1-acid glycoprotein glycosylation on wound healing